| Primary |
| Chronic Myeloid Leukaemia |
66.3% |
| Gastrointestinal Stromal Tumour |
5.9% |
| Prophylaxis |
5.9% |
| Acute Lymphocytic Leukaemia |
2.2% |
| Chromosome Analysis Abnormal |
2.2% |
| Graft Versus Host Disease |
1.8% |
| Hypertension |
1.8% |
| Myocardial Ischaemia |
1.8% |
| Chronic Myeloid Leukaemia Transformation |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
| White Blood Cell Count Increased |
1.5% |
| Acute Myeloid Leukaemia |
1.1% |
| Diabetes Mellitus |
1.1% |
| Urosepsis |
1.1% |
| Arthralgia |
0.7% |
| Blast Crisis In Myelogenous Leukaemia |
0.7% |
| Blood Magnesium Decreased |
0.7% |
| Blood Potassium Decreased |
0.7% |
| Dermatomyositis |
0.7% |
| Myelofibrosis |
0.7% |
|
| Death |
14.4% |
| Electrocardiogram Qt Prolonged |
14.4% |
| White Blood Cell Count Increased |
7.8% |
| Pyrexia |
6.7% |
| Rash |
6.7% |
| Pleural Effusion |
5.6% |
| Maternal Exposure During Pregnancy |
4.4% |
| Myocardial Infarction |
4.4% |
| Drug Ineffective |
3.3% |
| Drug Interaction |
3.3% |
| Normal Newborn |
3.3% |
| Pseudomonas Infection |
3.3% |
| Second Primary Malignancy |
3.3% |
| Vith Nerve Paralysis |
3.3% |
| Vomiting |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
| Blast Crisis In Myelogenous Leukaemia |
2.2% |
| Cerebrovascular Accident |
2.2% |
| Cholangitis Acute |
2.2% |
| Completed Suicide |
2.2% |
|
| Secondary |
| Chronic Myeloid Leukaemia |
60.9% |
| Acute Lymphocytic Leukaemia |
8.9% |
| Prophylaxis |
4.9% |
| Hypertension |
4.3% |
| Gastrointestinal Stromal Tumour |
3.4% |
| Diabetes Mellitus |
2.2% |
| Chromosome Analysis Abnormal |
1.8% |
| Hypothyroidism |
1.5% |
| Atrial Fibrillation |
1.2% |
| Graft Versus Host Disease |
1.2% |
| Nasopharyngitis |
1.2% |
| Prophylaxis Against Graft Versus Host Disease |
1.2% |
| White Blood Cell Count Increased |
1.2% |
| Benign Prostatic Hyperplasia |
0.9% |
| Blast Crisis In Myelogenous Leukaemia |
0.9% |
| Product Used For Unknown Indication |
0.9% |
| Relapsing Fever |
0.9% |
| Thyroid Disorder |
0.9% |
| Acute Lymphocytic Leukaemia Recurrent |
0.6% |
| Asthma |
0.6% |
|
| Thrombocytopenia |
13.5% |
| Electrocardiogram Qt Prolonged |
8.1% |
| White Blood Cell Count Decreased |
8.1% |
| Drug Resistance |
6.8% |
| Peripheral Arterial Occlusive Disease |
6.8% |
| Death |
5.4% |
| Metrorrhagia |
5.4% |
| Myocardial Infarction |
5.4% |
| Pleural Effusion |
5.4% |
| Neoplasm Malignant |
4.1% |
| Non-small Cell Lung Cancer |
4.1% |
| Pseudomonas Infection |
4.1% |
| White Blood Cell Count Increased |
4.1% |
| Blood Glucose Increased |
2.7% |
| Cholestasis |
2.7% |
| Completed Suicide |
2.7% |
| Dengue Fever |
2.7% |
| Drug Administration Error |
2.7% |
| Drug Interaction |
2.7% |
| Erythema |
2.7% |
|
| Concomitant |
| Chronic Myeloid Leukaemia |
26.2% |
| Product Used For Unknown Indication |
18.4% |
| Chronic Graft Versus Host Disease |
8.7% |
| Prophylaxis |
6.8% |
| Infection Prophylaxis |
5.8% |
| Acute Graft Versus Host Disease |
4.9% |
| Acute Lymphocytic Leukaemia |
4.9% |
| Acute Lymphocytic Leukaemia Recurrent |
3.9% |
| Antibiotic Therapy |
2.9% |
| B Precursor Type Acute Leukaemia |
1.9% |
| Gastric Ulcer |
1.9% |
| Gastrointestinal Stromal Tumour |
1.9% |
| Nausea |
1.9% |
| Pain |
1.9% |
| Premedication |
1.9% |
| Vomiting |
1.9% |
| Acute Myeloid Leukaemia |
1.0% |
| Antiviral Treatment |
1.0% |
| Blood Uric Acid |
1.0% |
| Bone Marrow Failure |
1.0% |
|
| Tachycardia |
11.1% |
| Blood Creatinine Increased |
7.4% |
| Renal Failure Acute |
7.4% |
| Renal Failure Chronic |
7.4% |
| Skin Disorder |
7.4% |
| Thrombocytopenia |
7.4% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Blast Cell Crisis |
3.7% |
| Chronic Myeloid Leukaemia |
3.7% |
| Death |
3.7% |
| Febrile Bone Marrow Aplasia |
3.7% |
| Leukocytosis |
3.7% |
| Lung Neoplasm Malignant |
3.7% |
| Myocardial Infarction |
3.7% |
| Neurotoxicity |
3.7% |
| Oedema |
3.7% |
| Organising Pneumonia |
3.7% |
| Pain |
3.7% |
| Productive Cough |
3.7% |
| Renal Vasculitis |
3.7% |
|
| Interacting |
| Product Used For Unknown Indication |
40.0% |
| Hiv Infection |
30.0% |
| Chronic Myeloid Leukaemia |
20.0% |
| Tuberculosis |
10.0% |
|
| Fluid Retention |
50.0% |
| Cardiac Failure |
16.7% |
| Drug Interaction |
16.7% |
| Tuberculosis |
16.7% |
|
